碧迪医疗(Becton Dickinson)

US · BDX #450 按市值排名上市于 1970

191.75 -2.01 -1.04%

实时 - 追踪5344个代码 - 心跳于495秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量减少了5家。
机构持股总比例基本持平。

机构持股

机构持股比例: 98.39% -0.07pp
机构数量: 1,675 -5
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund86.26%

Public Company3.81%

Private Company2.07%

Government Pension Fund1.87%

Sovereign Wealth Fund1.58%

Hedge Fund1.28%

Insurance Company0.79%

Family Office/Trust0.28%

Individual/Insider0.17%

Other1.90%

主要股东截至 2026-06-30

BlackRock 9.03% · 24.59M 股

Vanguard Capital Management, LLC 7.17% · 19.54M 股

State Street Global Advisors 5.51% · 15.00M 股

Vanguard Portfolio Management, LLC 5.50% · 14.97M 股

First Eagle Investment Management, LLC 5.07% · 13.82M 股

Geode Capital Management, LLC 2.99% · 8.14M 股

T. Rowe Price Group, Inc. 2.80% · 7.63M 股

MFS Investment Management 2.75% · 7.50M 股

Invesco Ltd. 2.66% · 7.25M 股

Putnam LLC 2.46% · 6.69M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 24次买入 · 21次卖出

姓名	职务	持股比例
Thomas Polen	Chairperson & CEO	0.04%
Timothy Ring	Independent Director	0.02%
Bilal Muhsin	Executive VP & President of Future Connected Care Segment	0.02%
Bertram Scott	Lead Independent Director	0.01%
Christopher Ian Jones	Independent Director	0.01%
Shana Neal	Executive Vice President	0.01%
Michael Feld	Executive VP & President of the Life Sciences Segment	0.01%
Christopher DelOrefice	Chief Financial Officer	0.01%
Roland Goette	Executive VP & President of EMEA	0.01%
Michael Garrison	Executive VP & President of Medical segment	0.00%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-27	Michael Feld	Executive VP & President of the Life Sciences Segment	Automatic Disposition	-76	$183.70
2026-09-01	vitor Roque	SVP of Finance, Business Units and Corporate Financial Planning & Analysis	Sale to Issuer	-190	--
2026-08-25	Michael Feld	Executive VP & President of the Life Sciences Segment	Automatic Disposition	-165	$188.49
2026-08-19	Michael Feld	Executive VP & President of the Life Sciences Segment	Sale to Issuer	-1,049	--
2026-08-12	Thomas Polen	Chairperson & CEO	Derivative Exercise and Sale	-43,278	$167.25–185.00
2026-08-10	Roland Goette	Executive VP & President of EMEA	Open Market Disposition	-2,438	$180.84
2026-08-05	Robert Huffines	Independent Director	Other Derivative Acquisition	+189	--
2026-08-05	Carrie Byington	Independent Director	Other Derivative Acquisition	+94	--
2026-07-26	Michael Feld	Executive VP & President of the Life Sciences Segment	Automatic Disposition	-75	$157.13
2026-07-01	Bilal Muhsin	Executive VP & President of Future Connected Care Segment	Sale to Issuer	-1,935	--
2026-06-30	Bilal Muhsin	Executive VP & President of Future Connected Care Segment	Other Acquisition	+14,342	--
2026-06-25	Michael Feld	Executive VP & President of the Life Sciences Segment	Automatic Disposition	-75	$152.80
2026-06-23	Michael Garrison	Executive VP & President of Medical segment	Automatic Disposition	-1,100	$145.66
2026-06-21	Manish Sinha	Executive Vice President	Initial Statement of Beneficial	0	--
2026-06-09	Michael Garrison	Executive VP & President of Medical segment	Automatic Disposition	-1,100	$151.48
2026-05-31	Thomas Polen	Chairperson & CEO	Derivative Exercise and Sale	-20,209	$126.16–146.35
2026-05-31	Peter Menziuso	Executive VP & President of Bd Interventional	Other Acquisition	+14,258	--
2026-05-31	Peter Menziuso	Executive VP & President of Bd Interventional	Initial Statement of Beneficial	0	--
2026-05-25	Michael Feld	Executive VP & President of the Life Sciences Segment	Automatic Disposition	-75	$147.35
2026-05-07	Robert Huffines	Independent Director	Other Derivative Acquisition	+210	--

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。